News & Events
July 30, 2020
C-Path Partners with CHDR to Expand Global CollaborationsThe Critical Path Institute and the Centre for Human Drug Research (CHDR) have joined forces to expand global collaborations for both organizations. The initiative brings together stakeholders from each side with the objective of increasing actionable solutions for drug development and public health. The partnership allows CHDR to become involved in other areas of interest......
January 4, 2019
At the IBD Biomarker Summit, Hosted by the Crohn’s & Colitis Foundation, C-Path Shares the Case for formation of an IBD Biomarker ConsortiumAt the IBD Biomarkers Summit, hosted by the Crohn’s & Colitis Foundation on October 17-18, 2018, in Newark, N.J., Critical Path Institute (C-Path) highlighted the need for an Inflammatory Bowel Disease (IBD) focused consortium with the goal to qualify biomarkers as tools to support IBD drug development programs. The two-day participatory event featured presentations and......
November 8, 2018
Profiles in Business with Tucson Metro Chamber
C-Path President and CEO Martha Brumfield, Ph.D., talks about today’s drug discovery process, C-Path’s global impact and what’s next for the organization on the Tucson Metro Chamber’s Profiles in Business podcast.
May 7, 2018
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and,......
April 26, 2018
CPTR Newsletter – April 2018CPTR Newsletter – April 2018 In this issue: ReSeqTB to be Adopted for WHO Surveillance of Drug-Resistant TB New Collaborations Expand TB-PACTS Database and Leverage Data for Analyses CPTR Workgroup Works to Advance Regulatory Qualification of LAM, a Promising New Biomarker TB-PBPK Model Progresses Toward EMA and FDA Qualification TB-ReFLECT Update: A Collaborative Effort......